Filing Flows › 60 Degrees Pharmaceuticals (SXTP) › Q4 2024
60 Degrees Pharmaceuticals (SXTP) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 27, 2025
60 Degrees Pharmaceuticals (SXTP) reported revenue of $242K for the fourth quarter 2024 (Q4 2024), +92% from a year earlier and +79% from the quarter before. Operating margin was -854.7%, net loss $2.0M (847.9% of revenue).
60 Degrees Pharmaceuticals, Q4 2024: revenue $242K (+92% year over year), operating margin -854.7%, net loss $2.0M, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $242K | +79% | +92% |
| Operating profit | −$2.1M | — | — |
| Net earnings | −$2.0M | — | — |
| Operating cash flow | −$1.6M | — | — |
What changed
Revenue was $242K in Q4 2024, up 92% year over year and up 79% from the previous quarter.
Gross margin was 46.7%. Operating costs exceeded revenue by $2.1M, an operating margin of -854.7%. The quarter ended with a net loss of $2.0M, narrower than the previous quarter's $2.2M loss. Minority interests bore $4K of it: to shareholders the quarter was a loss of $2.0M.
Operating cash flow was −$1.6M. Non-cash charges added back $16K of depreciation and amortization and $62K of share-based compensation. Working capital and other items added $333K.
Questions
What was 60 Degrees Pharmaceuticals' revenue in the fourth quarter 2024?
60 Degrees Pharmaceuticals (SXTP) reported revenue of $242K for the fourth quarter 2024 (Q4 2024), +92% from a year earlier and +79% from the quarter before.
Was 60 Degrees Pharmaceuticals profitable in the fourth quarter 2024?
Operating loss was $2.1M (-854.7% of revenue) and net loss $2.0M.